High Expression of ABCC1 Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 125-130

  Srimunta, Umaporn ^a   Sawanyawisuth, Kanlayanee ^a   Kraiklang, Ratthaphol ^a   Pairojkul, Chawalit ^a   Puapairoj, Anucha ^a   Titipungul, Tanin ^a   Hahnvajanawong, Chariya ^a   Tassaneeyakul, Wichittra ^a   Wongkham, Chaisiri ^a   Wongkham, Sopit ^a   Vaeteewoottacharn, Kulthida ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

ABC transporter expression; ABCC1; Bile duct cancer; ICC; Intrahepatic cholangiocarcinoma

Indexed keywords

ABC TRANSPORTER;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; GENETICS; HUMAN; INTRAHEPATIC BILE DUCT; LIVER TUMOR; METABOLISM; PROGNOSIS;

ATP-BINDING CASSETTE TRANSPORTERS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84874027077     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.125     Document Type: Article

References (20)

1. Andre T, Tournigand C, Rosmorduc O, et al (2004). Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 15, 1339-43.
2. Borel F, Han R, Visser A, et al (2012). Adenosine triphosphatebinding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology, 55, 821-32.
3. Chang XB (2007). A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev, 26, 15-37.
4. Chen L, Yan HX, Yang W, et al (2009). The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol, 50, 358-69.
5. Cho JY, Paik YH, Chang YS, et al (2005). Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 104, 2753-8.
6. Guo Y, Kock K, Ritter CA, et al (2009). Expression of ABCCtype nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res, 15, 1762-9.
7. Haber M, Smith J, Bordow SB, et al (2006). Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol, 24, 1546-53.
8. Henderson MJ, Haber M, Porro A, et al (2011). ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst, 103, 1236-51.
9. Hoffmann K, Shibo L, Xiao Z, et al (2011). Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res, 31, 3883-90.
10. Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51, 1-9.
11. Larbcharoensub N, Sornmayura P, Sirachainan E, et al (2011). Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. Histopathology, 59, 235-46.
12. Morise Z, Sugioka A, Tokoro T, et al (2010). Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol, 2, 58-64.
13. Nehls O, Oettle H, Hartmann JT, et al (2008). Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer, 98, 309-15.
14. Oguri T, Bessho Y, Achiwa H, et al (2007). MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther, 6, 122-7.
15. Plasschaert SL, de Bont ES, Boezen M, et al (2005). Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res, 11, 8661-8.
16. Robbiani DF, Finch RA, Jager D, et al (2000). The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)- dependent mobilization of dendritic cells to lymph nodes. Cell, 103, 757-68.
17. Shin HR, Oh JK, Masuyer E, et al (2010). Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia. Asian Pac J Cancer Prev, 11, 1159-66.
18. Tepsiri N, Chaturat L, Sripa B, et al (2005). Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol, 11, 2748-53.
19. Vander Borght S, Komuta M, Libbrecht L, et al (2008). Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int, 28, 1370-80.
20. Wang C, Maass T, Krupp M, et al (2009). A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol, 50, 1122-31.